trending Market Intelligence /marketintelligence/en/news-insights/trending/SgfPZkVyAqKVkP6RTw4AXw2 content esgSubNav
In This List

US FDA rejects AcelRx Pharmaceuticals' pain drug

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Blog

Perspectives from China: Chinese M&A in 2022


US FDA rejects AcelRx Pharmaceuticals' pain drug

AcelRx Pharmaceuticals Inc. said the U.S. Food and Drug Administration rejected its new drug application for DSUVIA to treat moderate-to-severe acute pain.

AcelRx submitted the application in December 2016. In a complete response letter, the U.S. FDA requested additional data on at least 50 patients and certain labeling changes in usage directions.

The 2016 application was supported by results from the entire ARX-04 clinical program, including data from four trials that showed improvement in pain intensity within 15 to 30 minutes of dosage.

"We believe the recommendations stated in the CRL are manageable and plan to fully cooperate with the FDA," AcelRX CEO Vincent Angotti said in a statement.